A. Menarini Diagnostics announces an exclusive Distribution Agreement with Sinocare to register, promote, distribute, and market a new Sinocare 3rd Generation Continuous Glucose Monitoring (CGM) System within reimbursed markets. This landmark agreement grants A. Menarini Diagnostics exclusive rights to introduce this health technology to more than 20 jurisdictions in Europe.

1.5 Sequencer with the Highest Throughput In 2020, the DNBSEQ-T7 Gene Sequencer of Wuhan MGI Technology Co., Ltd. (hereinafter referred to as “MGI”) was approved (Registration No.: G.X.Z.Z. 20,203,220,061). It..

Roche Diagnostics Partners with Sanya Yazhou Bay Science and Technology City to Launch Public Innovation Platform for Bioscience Diagnostics On November 18, Roche Diagnostics China and the..

The US Food and Drug Administration has issued its anticipated guidance for drug and device makers on the use of circulating tumor DNA tests in clinical trials of drugs for early-stage cancer, embracing the increasingly widespread use of these tests to genotype patients as well as their emerging value to enrich trials by identifying patients more likely to benefit from adjuvant or neoadjuvant treatment.

Devyser has received IVDR approval for its non-invasive fetal RHD screening product. This marks the first approval of a Class D product, the highest risk class under the new, comprehensive European regulation that came into force in May 2022.

The Egypt Healthcare Authority (EHA), Roche Diagnostics and Roche Pharmaceuticals have signed a memorandum of understanding (MOU) to advance digital pathology in Egypt.

Canon Medical Systems USA is proud to announce the launch of its AI-powered Automation Platform, an advanced, zero-click solution that leverages deep learning technology to streamline clinical workflows. Designed to deliver fast, actionable results, this innovative platform integrates seamlessly from scanner to clinical decision-making, empowering healthcare providers with precise tools to help with patient triage and confident treatment planning.

Suraksha Diagnostic Ltd, an integrated diagnostic chain based in Kolkata, has successfully raised ₹254 crore from anchor investors ahead of its initial public offering (IPO).

Original from: QIAGEN QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of two new tools for designing and ordering custom solutions that can be used to support microbial anal..

Original from: 360dx Hong Kong-based genomic testing firm Prenetics on Wednesday announced that its Q3 revenues rose 59 percent year over year. The firm reported revenue of $7.8 million, up..

Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, today announced a new collaboration with UK Biobank to create the world’s first comprehensive, large-scale epigenetic dataset.

QIAGEN today announced the inclusion of the QIAcuityDx digital PCR System in the Australian Register of Therapeutic Goods (ARTG). This pivotal addition to QIAGEN’s portfolio is now expanding digital PCR into clinical diagnostics, enabling labs to harness its precision and efficiency for applications in oncology and infectious diseases. The instrument and accessories are IVDR-certified.

Original from: Roche Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (“Poseida”, NASDAQ: PSTX), a public ..

1.4 Automatic Database Building Database building is a link to high-throughput sequencing. Manual database building is cumbersome and time-consuming; it requires multiple labs, and it is difficult to meet the re..

Agilent Technologies Inc. (NYSE: A) today announced a new organizational structure to accelerate the company's operational transformation to drive higher growth through a market-focused, customer-centric enterprise strategy. The new structure, including new leadership roles, takes effect immediately.